ERBB2 and ductal breast carcinoma in situ: Gorringe et al. [23] used the molecular inversion probe assay to profile CNVs in DCIS with and without recurrence, and they showed that 1q gain and 8p loss are among the most frequent CNVs in 8 HER2-positive non-recurrent DCIS and 9 HER2-positive recurrent DCIS.